Description: Fusion Antibodies PLC, formerly Fusion Antibodies, Ltd., is a United Kingdom-based cancer therapeutics developer. The Company develops and commercializes antibody-based therapeutics for cancer. The Company develops a range of antibody engineering services based around monoclonal antibodies. It focuses in the expression and purification of recombinant proteins and chimeric antibodies for the research, diagnostic and therapeutic markets. Its technology generates target specific antibodies from protein antigens. The Company's therapeutic and diagnostic research and development are offered as a service to pharmaceutical, biopharmaceutical and academic researchers.
Home Page: www.fusionantibodies.com
FAB Technical Analysis
1 Springbank Road
Belfast,
BT17 0QL
United Kingdom
Phone:
44 28 9043 2800
Officers
| Name | Title |
|---|---|
| Mr. James Fair | CFO, Company Sec. & Director |
| Dr. Richard John Buick Ph.D. | Chief Scientific Officer & Director |
| Dr. Adrian Kinkaid Ph.D. | CEO & Director |
| Prof. Jim Johnston | Founder |
| Mr. Hugh Morgan Ph.D. | Director of Operations |
| Dr. Paul Gerard Kerr | Consultant |
Exchange: LSE
Country: UK : United Kingdom
Currency: Pence sterling (p)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Life Sciences Tools & Services |
| GIC Sub-Industry: | Life Sciences Tools & Services |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.1976 |
| Price-to-Sales TTM: | 2.5577 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 55 |